OL Research supplies research materials exclusively for laboratory use. All products are handled and distributed in accordance with UK regulations governing research chemicals. We do not advise, support or condone the use of research chemicals in humans or animals.

BPC-157 UK Research Guide 2026: Mechanism & Compliance

For laboratory and investigational use only. This article is a research-focused overview of a synthetic pentadecapeptide studied in preclinical models. Nothing here is medical advice, and BPC-157 is not authorised by the MHRA for any human or veterinary use.

BPC-157 — short for Body Protective Compound 157 — is one of the most widely discussed peptides in 2020s preclinical research. UK-based laboratories ordering it in 2026 face a steeper compliance bar than they did three years ago, alongside growing scrutiny of supplier provenance, batch purity, and identity-verification standards. This guide walks through what BPC-157 actually is at a molecular level, how researchers describe its mechanism in animal models, what to look for in a UK-supplied vial, and the regulatory framing that determines how it can lawfully be held and used.

OL Research supplies BPC-157 (and 200+ other research compounds) only to UK laboratories, contract research organisations, and credentialled investigators. Throughout this guide we will link to the related compounds, calculators and quality documents on our site so you can drill into a specific area without leaving the knowledge hub.

What is BPC-157?

BPC-157 is a synthetic, stable pentadecapeptide — 15 amino acids in a single chain — derived from a sequence first identified in human gastric juice. The full amino-acid sequence is:

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

The peptide was first isolated and characterised by Sikiric and colleagues at the University of Zagreb in the 1990s, who described its unusual stability in gastric juice at human body temperature — a property that distinguishes it from most short peptides, which degrade rapidly in acidic conditions. That stability is the reason it has become a workhorse compound in gastrointestinal, musculoskeletal and neurological injury models.

In supplied form, BPC-157 is a white, lyophilised (freeze-dried) powder typically presented in 5 mg or 10 mg sealed glass vials under inert gas. It is highly soluble in bacteriostatic water (BAC water) and stable in solution for ~30 days when refrigerated.

OL Research stocks the two most common research presentations:

  • BPC-157 10mg — 10 mg lyophilised vial, the standard size for most research protocols
  • BPC-157 5mg — 5 mg vial, useful for shorter studies or pilot work
  • BPC-157 + TB-500 20mg — a pre-blended 1:1 BPC-157 / TB-500 preparation widely used in tissue-repair research models

Each batch is independently characterised for HPLC purity, mass-spectrometry identity confirmation, and endotoxin status — covered in the Quality section below.

Mechanism of action — what preclinical research shows

The literature on BPC-157 is preclinical: rats, mice, in-vitro tissue, and a small number of large-animal studies. No mechanism described below has been demonstrated in human trials, and every claim in published work refers to controlled laboratory conditions.

Across the published corpus, four mechanisms appear repeatedly:

1. Pro-angiogenic effects via VEGFR-2. Multiple studies report that BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR-2) expression and accelerates the formation of new capillary networks in wound-bed and tendon-injury models. This is the proposed mechanism behind the much-cited tendon-to-bone healing observations.

2. Modulation of the nitric oxide (NO) system. BPC-157 appears to interact with the endothelial nitric oxide synthase (eNOS) pathway. Researchers have reported a dose-dependent counter-regulation of L-NAME (an NO-synthase inhibitor) and L-arginine (the NO precursor), suggesting BPC-157 sits inside the NO axis rather than acting independently of it. This mechanism has been invoked to explain observations in cardiovascular and gastrointestinal models.

3. Growth-hormone receptor upregulation. In tendon fibroblast cultures, BPC-157 has been reported to increase the expression of the growth-hormone receptor — a candidate explanation for the connective-tissue effects seen in vivo. This effect is independent of systemic growth hormone levels.

4. CNS and neurotransmitter interactions. A smaller but consistent body of work describes interactions with dopaminergic and serotonergic systems, including reports of attenuated effects of dopaminergic neurotoxins (MPTP, methamphetamine) in rodent models. These observations are why several recent groups have proposed BPC-157 as a candidate compound for peripheral nerve and traumatic brain injury research.

Crucially, the preclinical mechanism does not imply translation to humans. The bioavailability, stability and pharmacokinetics of BPC-157 in human subjects have not been formally characterised in any MHRA-approved trial as of 2026.

Research applications in 2026

The five preclinical research areas most active in current publications are:

  • Musculoskeletal injury models — rotator-cuff, Achilles, and patellar tendon transections in rats; ligament reconstruction
  • Gastrointestinal models — gastric ulcer, ileitis, fistula closure, short-bowel syndrome
  • Neurological models — peripheral nerve transection, traumatic brain injury, spinal cord contusion
  • Cardiovascular models — vascular endothelial recovery after experimental injury
  • Wound healing — open-wound closure rate, scar tissue quality, bone-defect healing

If you are designing a study in one of these areas, the most common companion compound in published protocols is TB-500 (Thymosin Beta-4 fragment). The two are often combined; many labs simply order the BPC-157 + TB-500 20mg blend rather than maintaining separate stocks.

Quality considerations: HPLC purity, mass spec, and identity verification

Not all “BPC-157” sold online is BPC-157. Independent testing of grey-market vials has repeatedly found peptides at low purity, sequence variants, or — in the worst cases — entirely different compounds. The four things to verify on every batch:

  1. HPLC purity ≥98%. Below this threshold, you are introducing uncharacterised contaminants into your experimental system, which will appear in your error bars.
  2. Mass-spectrometry identity match. Independent testing should show the expected mass (1419.5 Da) within instrument tolerance, confirming the sequence is genuinely BPC-157 and not a near-neighbour peptide.
  3. Endotoxin status. Even at lab scale, residual endotoxin will produce confounding inflammatory effects. Reputable suppliers record endotoxin units explicitly.
  4. Batch traceability. Lot number on the vial label should map to dated, lab-attributed test results — not a generic “research grade” statement that could apply to any batch.

If the supplier you are evaluating cannot evidence all four items per batch, treat the product as uncharacterised regardless of how the listing is marketed.

Reconstitution and storage

Lyophilised BPC-157 is stable at room temperature for the duration of normal shipping, but should be refrigerated on arrival (2–8 °C) and reconstituted before use with bacteriostatic water — specifically BAC water, which contains 0.9 % benzyl alcohol as a preservative. Plain sterile water lacks the bacteriostatic component and is unsuitable for any reconstituted solution intended for more than single-use within hours.

Worked reconstitution example:

A 10 mg BPC-157 vial reconstituted with 2 ml of BAC water yields a 5 mg/ml — i.e. 5,000 µg/ml — working solution. At a 250 µg per-aliquot research dose, that single 10 mg vial supplies 40 aliquots. Adjust as needed; our reconstitution calculator handles the arithmetic for any vial size and target concentration.

Once reconstituted:

  • Refrigerate at 2–8 °C. Do not freeze the reconstituted solution unless your protocol requires it; freeze–thaw cycles can degrade the peptide.
  • 30-day in-use stability. Most labs treat reconstituted BPC-157 in BAC water as usable for 30 days; some published protocols extend this to 60 days at lower temperatures, but verify with your own QC before adopting.
  • Avoid sodium chloride for dilution. Chloride ions can accelerate peptide bond hydrolysis in concentrated solutions over weeks.

For larger studies or multi-aliquot work, the 10 ml BAC water vial is more economical than the standard 3 ml.

UK research compliance in 2026

Compliance is where most UK researchers get caught out, because the rules sit at the intersection of medicines law, consumer protection law, and import controls.

Status: BPC-157 is not a medicinal product. It is not licensed by the MHRA for human or veterinary use. It is not a food supplement. It is sold exclusively for laboratory and investigational research use and must be held and used as such.

Practical implications:

  • BPC-157 may not lawfully be administered to humans or animals outside an authorised clinical or veterinary trial.
  • It may not be marketed, advertised, or supplied for any form of personal use, weight loss, performance enhancement, or therapeutic purpose.
  • Institutional research holding BPC-157 should record lot numbers, COAs, storage temperatures, and disposal in an inventory that satisfies the host institution’s chemical hygiene plan.
  • Importers should retain shipping documentation for at least three years.

Suppliers that market BPC-157 as a wellness, recovery, or longevity compound are operating outside the rules. Choosing a supplier that explicitly limits its marketing and customer base to research contexts protects both your institution and the supplier’s ability to keep operating.

OL Research’s full quality, compliance, and research-use position is documented on our Knowledge Hub.

Common research mistakes

Across years of supporting UK laboratories, the recurring avoidable mistakes are:

  • Reconstituting in plain sterile water — no preservative, contamination risk within hours.
  • Reconstituting in saline — chloride-mediated degradation over the 30-day in-use window.
  • Storing reconstituted vials at room temperature — drastically shortens stability.
  • Mixing BPC-157 with other peptides in a single vial before stability is validated — interaction effects on shelf life are not always benign.
  • Confusing micrograms and milligrams in dosing calculations. A factor-of-1000 error is the single most common protocol incident and a key reason we built a calculator.
  • Discarding batch documentation. The lot number, purity figure and date are the only evidence you held a characterised compound — keep them with your records.

Frequently asked questions

Is BPC-157 legal to hold in the UK? Yes, for laboratory and investigational research use. It is not lawful to administer to humans or animals outside an authorised trial, and it cannot be marketed for personal use.

What is the difference between BPC-157 5mg and BPC-157 10mg? Identical compound and identical purity grade — only the quantity per vial differs. The 10 mg vial is more economical per milligram for larger studies; the 5 mg vial suits pilot work or short studies.

What volume should I reconstitute with? A common starting point is 2 ml of BAC water in a 10 mg vial (5 mg/ml). Adjust to your aliquot size — our reconstitution calculator handles the arithmetic.

How long does reconstituted BPC-157 last? ~30 days at 2–8 °C in bacteriostatic water is the standard working assumption. Some protocols extend this; validate with your own QC.

How is purity verified? HPLC for purity (target ≥98 %) and mass spectrometry for identity (expected ~1419.5 Da). Endotoxin status is also routinely tested. The Quality section above lists the four data points a research buyer should expect per batch.

Can BPC-157 be combined with TB-500? Yes — many published preclinical protocols co-administer the two. For convenience, OL Research stocks a pre-blended BPC-157 + TB-500 20mg (10 mg BPC-157 + 10 mg TB-500) so labs can avoid two separate reconstitutions.

Further reading

References (preclinical literature)

Readers can locate the full corpus of BPC-157 preclinical research on PubMed using the search term “Sikiric BPC 157” (links below open a PubMed search relevant to each line — not a single paper). Key foundational and review papers include:

  • Sikiric P et al. Stable gastric pentadecapeptide BPC 157 and angiogenesis — multiple review articles (Current Pharmaceutical Design, J Physiol Pharmacol). PubMed search
  • Sikiric P et al. Stable gastric pentadecapeptide BPC 157 in the therapy of muscle and tendon injuries — preclinical review series. PubMed search
  • Chang CH et al. BPC-157 enhances growth-hormone receptor expression in tendon fibroblasts — in-vitro mechanism paper. PubMed search
  • Vukojević J et al. Rapid recovery of damaged tissues by stable gastric pentadecapeptide BPC 157 — review of musculoskeletal models. PubMed search
  • Sikiric P et al. BPC 157 and the nitric oxide system in the gastrointestinal tract — mechanism work on the NO axis. PubMed search
  • Vukojević J et al. BPC 157 and central nervous system / neurotoxin attenuation — dopaminergic / serotonergic interactions in rodent models. PubMed search

Final note: Every claim in this article refers to published preclinical research. BPC-157 has not been approved by the MHRA for any human or veterinary use, and OL Research supplies it only to UK laboratories and credentialled investigators for research purposes.

Last reviewed: 2026-05-29 · Drafted by OL Research · For laboratory and investigational research use only.